Cue Biopharma (CUE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $38.67 (+2.19%), Market cap $0.08B, 52-week low–high $0.18 ~ $35.73.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as
Financial statements, price targets, institutional (13F) holdings and related news for Cue Biopharma are updated in real time on BlackAll Trade.
Cue Biopharma trades at $38.67 (+2.19%). Real-time quotes and charts are available on BlackAll Trade.
Cue Biopharma has a market cap of about $0.08B.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United S